Comprehensive metabolomic profiling of plasma from patients (pts) with metastatic urothelial carcinoma (mUC) receiving immune checkpoint inhibitors (ICI) or platinum-based chemotherapy (PBC).

被引：1
|
作者：
El Zarif, Talal
Adib, Elio
Clish, Clary
Shukla, Sachet A.
Freeman, Dory
Thomas, Jonathan
Ravi, Praful
Tuff, Martha
McGregor, Bradley Alexander
Mantia, Charlene
Ravi, Arvind
Sonpavde, Guru P.
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA
[3] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
[4] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA
[5] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 06期
关键词：
D O I：
10.1200/JCO.2022.40.6_suppl.565
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
565
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Multiplexed autoantibody (AA) profiling of patients (pts) with metastatic urothelial carcinoma (mUC) receiving immune checkpoint inhibitors or platinum-based chemotherapy.
    Sonpavde, Guru P.
    Freeman, Dory
    Adib, Elio
    El Zarif, Talal
    Thomas, Jonathan
    Nuzzo, Pier Vitale
    Ravi, Arvind
    Tuff, Martha
    Mantia, Charlene
    McGregor, Bradley Alexander
    Berchuck, Jacob E.
    Budde, Petra
    Rupieper, Elena
    Gajewski, Jana
    McDaid, Ronan
    Schbuert, Ann-Sophie
    Braeutigam, Manuel
    Zucht, Hans-Dieter
    Ravi, Praful
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [2] Immunological correlates of response to immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (mUC) patients (pts)
    Tzeng, Alice
    Diaz-Montero, C. Marcela
    Rayman, Patricia A.
    Kim, Jin Sub
    Pavicic, Paul G.
    Finke, James
    Barata, Pedro C.
    Lamenza, Marcelo
    Devonshire, Sarah
    Schach, Kim
    Emamekhoo, Hamid
    Ernstoff, Marc S.
    Hoimes, Christopher J.
    Rini, Brian I.
    Garcia, Jorge A.
    Gilligan, Timothy D.
    Ornstein, Moshe Chaim
    Grivas, Petros
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [3] Comprehensive immune profiling of patients (pts) with metastatic urothelial cancer (mUC) or renal cell cancer (mRCC) receiving immune checkpoint inhibitors (CPIs)
    Lavoie, Jean-Michel
    Nissen, Michael
    Baichoo, Priya
    Nappi, Lucia
    Khalaf, Daniel Joseph
    Kollmannsberger, Christian K.
    Chi, Kim N.
    Weng, Andrew
    Eigl, Bernhard J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [4] Response to platinum-based therapy (PBT) and immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (mUC) patients (pts) with genomic alterations (GA) in homologous recombination repair (HRR) genes
    Mendiratta, Prateek
    Loehr, Andrea
    Simmons, Andrew
    Barata, Pedro C.
    Klek, Stefan
    Pritchard, Amy
    Emamekhoo, Hamid
    Funchain, Pauline
    Sohal, Davendra
    Ali, Siraj Mahamed
    Gilligan, Timothy D.
    Ornstein, Moshe Chaim
    Garcia, Jorge A.
    Rini, Brian I.
    Grivas, Petros
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [5] Effect of concurrent proton pump inhibitors (PPI) use in patients (pts) treated with immune checkpoint inhibitors (ICI) for metastatic urothelial carcinoma (mUC)
    Morales-Barrera, Rafael
    Vidal Casinello, Natalia
    Bonfill, Teresa
    Domenech, Montserrat
    Suarez Rodriguez, Cristina
    Puente, Javier
    Giner Joaquin, Julia
    Figols, Mariona
    Galante, Isabel
    Carrion, Albert
    Lopez, Hector
    Gonzalez, Macarena
    Roche, Sarai
    Mateo, Joaquin
    Gallardo Diaz, Enrique
    Fernandez Saez, Carlos
    Valverde Morales, Claudia Maria
    de Torres, Ines
    Morote, Juan
    Carles, Joan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [6] The role of previous radical local treatment (RLT) on the outcome of immune checkpoint inhibitors (ICI) in patients (pts) with metastatic urothelial carcinoma (mUC)
    Morales-Barrera, Rafael
    Vidal Casinello, Natalia
    Domenech, Montserrat
    Bonfill, Teresa
    Puente, Javier
    Figols, Mariona
    Giner Joaquin, Julia
    Gonzalez, Macarena
    Lozano, Fernando
    Lopez, Hector
    Galante, Isabel
    Mast, Richard
    Serra Hernandez, Ester
    Eugenia Semidey, Maria
    Serrano, Cesar
    Gallardo Diaz, Enrique
    Suarez Rodriguez, Cristina
    Maldonado, Xavier
    Morote, Juan
    Carles, Joan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [7] Association of biomarkers and outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) treated with immune checkpoint inhibitors (ICIs).
    Reyes, Kevin R.
    Zhang, Li
    Zhu, Xiaolin
    Jindal, Tanya
    Deshmukh, Prianka
    de Kouchkovsky, Ivan
    Kumar, Vipul
    Maldonado, Edward
    Kwon, Daniel H.
    Chan, Emily
    Porten, Sima P.
    Borno, Hala
    Bose, Rohit
    Desai, Arpita
    Aggarwal, Rahul Raj
    Small, Eric Jay
    Fong, Lawrence
    Chou, Jonathan
    Friedlander, Terence W.
    Koshkin, Vadim S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [8] Characterizing immune-genomic signatures associated with response to immune checkpoint inhibitors (ICI) in patients with metastatic urothelial carcinoma (mUC)
    Pramod, Nikhil
    Dawsey, Scott
    Pavicic, Paul G.
    Lodha, Roshan
    Patgunarajah, Ubenthira
    Nair, Monica
    Ornstein, Moshe Chaim
    Gilligan, Timothy D.
    Wee, Christopher Eing
    Mian, Omar Y.
    Nizam, Amanda
    Nguyen, Jane
    Diaz-Montero, C. Marcela
    Gupta, Shilpa
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [9] Treatment and outcome after Immune checkpoint inhibitors (ICI) in metastatic Urothelial Carcinoma (mUC): A European perspective
    Lista, A. Gomez de Liano
    Necchi, A.
    Lavaud, P.
    Carles Galceran, J.
    Castellano, D.
    Ravaud, A.
    Duran, I.
    van Dijk, N.
    Giannatempo, P.
    Loriot, Y.
    Morales Barrera, R.
    De Velasco Oria De Rueda, G.
    Lefort, F.
    Martinez Bernal, G.
    Raggi, D.
    Gross-Goupil, M.
    Powles, T.
    van der Heijden, M.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [10] Enfortumab-vedotin for metastatic urothelial carcinoma refractory to platinum-based chemotherapy and immune checkpoint inhibitors: A single institution experience
    Mikami, H.
    Endo, Y.
    Akatsuka, J.
    Kimura, G.
    Takeda, H.
    Ikuma, S.
    Taniuchi, M.
    Hasegawa, H.
    Toyama, Y.
    Shibasaki, M.
    Kondo, Y.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S1566 - S1566
12345